Physician profile
Taylor Ladd
NPI 1316643679
$1,478.52
in general payments reported to CMS, 2019-2025
15 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $471 · 2024: $554 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $671.50 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $236.59 | 2023-2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $179.83 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $86.10 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.71 | 2024-2025 | Caplyta |
| Lundbeck LLC | $39.03 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $37.38 | 2023-2024 | Auvelity, Sunosi |
| Kerecis Limited | $34.04 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $31.15 | 2023-2025 | |
| Neos Therapeutics, LP | $24.17 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $23.22 | 2025 | Dyanavel Xr |
| Altathera Pharmaceuticals LLC | $20.23 | 2025 | Sotalol Hydrochloride |
| Vanda Pharmaceuticals INC. | $18.26 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $15.35 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $12.96 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.